Bernhard Kiss1, Fiona C Burkhard1, George N Thalmann2. 1. Department of Urology, University of Bern, 3010, Bern, Switzerland. 2. Department of Urology, University of Bern, 3010, Bern, Switzerland. George.thalmann@insel.ch.
Abstract
INTRODUCTION: Muscle invasive bladder cancer is an unforgiving disease, and if untreated, it leads to death within 2 years of the diagnosis in >85 % of the patients. Long-term oncologic efficacy remains the ultimate standard that all procedures have to be measured by. In the past decades, open radical cystectomy (RC), extended pelvic lymph node dissection (PLND), and urinary diversion have been established as the gold standard. In the last few years, however, growing attention has been set on robotic-assisted radical cystectomy (RARC). RESULTS: Even in the very long term, open RC has good oncological results and if an ileal neobladder is performed excellent functional results. Follow-up of patients after open RC exceeds more than a decade which is unsurpassed by any other technique. Its outcomes have been proven to be durable and cost-effective. Least perioperative complications as well as best oncological and functional results can be achieved if open RC and urinary diversion were performed in a high-volume hospital by high-volume surgeons and an experienced team. CONCLUSIONS: Despite upcoming new technologies such as RARC, open RC following extended (PLND) remains the gold standard treatment for high-grade muscle invasive bladder cancer.
INTRODUCTION:Muscle invasive bladder cancer is an unforgiving disease, and if untreated, it leads to death within 2 years of the diagnosis in >85 % of the patients. Long-term oncologic efficacy remains the ultimate standard that all procedures have to be measured by. In the past decades, open radical cystectomy (RC), extended pelvic lymph node dissection (PLND), and urinary diversion have been established as the gold standard. In the last few years, however, growing attention has been set on robotic-assisted radical cystectomy (RARC). RESULTS: Even in the very long term, open RC has good oncological results and if an ileal neobladder is performed excellent functional results. Follow-up of patients after open RC exceeds more than a decade which is unsurpassed by any other technique. Its outcomes have been proven to be durable and cost-effective. Least perioperative complications as well as best oncological and functional results can be achieved if open RC and urinary diversion were performed in a high-volume hospital by high-volume surgeons and an experienced team. CONCLUSIONS: Despite upcoming new technologies such as RARC, open RC following extended (PLND) remains the gold standard treatment for high-grade muscle invasive bladder cancer.
Entities:
Keywords:
Muscle invasive bladder cancer; Open radical cystectomy
Authors: Roman Mayr; Matthias May; Thomas Martini; Michele Lodde; Armin Pycha; Evi Comploj; Wolf F Wieland; Stefan Denzinger; Wolfgang Otto; Maximilian Burger; Hans-Martin Fritsche Journal: BJU Int Date: 2012-02-07 Impact factor: 5.588
Authors: Bertram Yuh; Timothy Wilson; Bernie Bochner; Kevin Chan; Joan Palou; Arnulf Stenzl; Francesco Montorsi; George Thalmann; Khurshid Guru; James W F Catto; Peter N Wiklund; Giacomo Novara Journal: Eur Urol Date: 2015-01-02 Impact factor: 20.096
Authors: Bernard H Bochner; Guido Dalbagni; Daniel D Sjoberg; Jonathan Silberstein; Gal E Keren Paz; S Machele Donat; Jonathan A Coleman; Sheila Mathew; Andrew Vickers; Geoffrey C Schnorr; Michael A Feuerstein; Bruce Rapkin; Raul O Parra; Harry W Herr; Vincent P Laudone Journal: Eur Urol Date: 2014-12-08 Impact factor: 20.096
Authors: Joseph A Pettus; Hikmat Al-Ahmadie; Daniel A Barocas; Theresa M Koppie; Harry Herr; S Machele Donat; Guido Dalbagni; Victor E Reuter; Semra Olgac; Bernard H Bochner Journal: Eur Urol Date: 2007-07-26 Impact factor: 20.096
Authors: Syed Johar Raza; Timothy Wilson; James O Peabody; Peter Wiklund; Douglas S Scherr; Ali Al-Daghmin; Shiva Dibaj; Muhammad Shamim Khan; Prokar Dasgupta; Alex Mottrie; Mani Menon; Bertram Yuh; Lee Richstone; Matthias Saar; Michael Stoeckle; Abolfazl Hosseini; Jihad Kaouk; James L Mohler; Koon-Ho Rha; Gregory Wilding; Khurshid A Guru Journal: Eur Urol Date: 2015-05-16 Impact factor: 20.096